To Top

Community

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Contribution
Biologics Manufacturing

AGC Triples U.S. Biopharmaceutical Production Capacity

PR-M12-18-NI-066
Market Prediction

Emerging Medical Device Market Expected to Exceed $400 Billion by 2023

Patient Adherence

Sempre Health and UPMC Health Plan Expand Program that Improves Affordability and Adherence for Critical Medications

PR-M12-18-NI-064
Collaboration

Marken and TrakCel Collaborate to Serve Cell and Gene Trials

PR-M12-18-NI-087
Medical Device

Statement from Jeff Shuren, Director of the CDRH, on Updated Safety Communication About Rates of Duodenoscope Contamination from Preliminary Postmarket Data

PR-M12-18-NI-062
Surgical Robots

The global Surgical Robots Market is Projected to Reach 6.5 billion by 2023 from USD 3.9 billion in 2018 at a CAGR of 10.4%

PR-M12-18-NI-061
Public Offering

Biohaven Announces Proposed Public Offering of Common Shares

PR-M12-18-NI-060
Clinical Trial Patient Populations

Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials

PR-M12-18-NI-059
Cell Expansion

Cell Expansion Market to Reach US $26 Billion by 2024, Says TMR

PR-M12-18-NI-058
Investment

GenEdit Closes $8.5 million Series Seed Financing

PR-M12-18-NI-056
Approval

World-first Approval For Multiple Myeloma Drug APLIDIN(R)

PR-M12-18-NI-055
Drug Development

Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015

PR-M12-18-NI-054
Acquisition

Therapix Biosciences Provides Update Regarding FSD Acquisition

PR-M12-18-NI-052
Presentation

Abbott to Present at J.P. Morgan Healthcare Conference

PR-M12-18-NI-051
Appointment

BiomX Appoints Sailaja Puttagunta as Chief Medical Officer

PR-M12-18-NI-048
FDA

XOSPATA® (gilteritinib) Available at Biologics by McKesson

PR-M12-18-NI-045
Pricing

Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering

Expansion

NYCEDC Grants $1M To Quentis Therapeutics For Expansion of LifeSci Space in West Harlem

PR-M12-18-NI-043
Financing

Impel NeuroPharma Closes $67.5 Million Series D Financing

PR-M12-18-NI-040
Immuno-Oncology

Immuno-oncology Development Trends and Opportunities

PR-M12-18-NI-038
Alzheimer's Disease

First Drug Candidate From Eisai-UCL Research Collaboration To Enter Alzheimer's Disease Clinical Trials

PR-M12-18-NI-037
Financial Results

Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend

PR-M12-18-NI-036
Appointment

Roche Exec Moves to Gilead

PAO-M12-18-NI-010
Expansion

Investor Group Purchases 110-Acre Pharmaceutical Campus in Huntsville, Alabama

PR-M12-18-NI-047
M&A

Histo-Scientific Research Laboratories and Vet Path Services Merge

PR-M12-18-NI-046
Gene and Cell Therapy

PPD Expands GMP Lab Testing Capabilities for Biologics

PR-M12-18-NI-035
Stem Cells

USRM announces U.S. Stem Cell Clinic Expansion of Products and Services

PR-M12-18-NI-033
FDA Acceptance

FDA Accepts Filing of New Estrogen-free Oral Contraceptive Developed by Exeltis

PR-M12-18-NI-030
FDA Approval

Olympus Spiration® Valve System Is FDA Approved for the Endobronchial Treatment of Emphysema

PR-M12-18-NI-029
Clinical Trial

Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome

PR-M12-18-NI-028
Appointment

Sartorius Supervisory Board Appoints Two New Executive Board Members

PR-M12-18-NI-027
License Agreement

Ablexis Announces Licensing Agreement with Allogene Therapeutics

PR-M12-18-NI-026
Leukemia

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

PR-M12-18-NI-025
Obesity

The Anti-Obesity Drugs Market Will Register a CAGR of Almost 8% by 2023

PR-M12-18-NI-024
Chronic Migraine

Migraine Drugs Market Size Worth $7.8 Billion by 2025 | CAGR: 18.0%: Grand View Research, Inc.

PR-M12-18-NI-023
Clinical Trials

Late-Breaking Clinical Trials Advance Targeted Therapies for Patients with CLL and Multiple Myeloma

PR-M12-18-NI-018
Phase 3

New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma

PR-M12-18-NI-019
Oncology

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR

PR-M12-18-NI-017
Bayer

Cutbacks and Divestitures Planned at Bayer

PAO-M12-18-NI-004
Alzheimer's Disease

Ocular Technology Provides Early Detection of Alzheimer's Disease

PR-M12-18-NI-014
Immunotherapy

Global Cancer Immunotherapy Market 2017-2027 Featuring Leading Players - Pfizer, Merck, Amgen and Roche

PR-M12-18-NI-012
Cystic Fibrosis

Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations

PR-M12-18-NI-013
ADC

Ajinomoto Bio-Pharma Services Introduces AJICAP Bioconjugation Technology for ADC Manufacturing

PR-M12-18-NI-010
Market Prediction

The global single-use bioprocessing market is anticipated to reach revenues of approximately $7 billion by 2024

PR-M12-18-NI-009
Stem Cells

Platelets Grown from Stem Cells May be Alternative to Donated Platelets

PR-M12-18-NI-006
FDA Approval

FDA Approves First Biosimilar for Treatment of Adult Patients with Non-Hodgkin's Lymphoma

PR-M12-18-NI-004
Partnership

WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies

PR-M12-18-NI-003
Research

Researchers Regrow Hair on Wounded Skin

PR-M12-18-NI-002
Market Prediction

The Global Cell Therapy Market Size is Expected to Reach USD 7.92 Billion by 2025

PR-M11-18-NI-106
Probiotics

Probiotic Ingredients Market Worth Over $3 Billion by 2024: Global Market Insights, Inc.

PR-M11-18-NI-103
Respiratory

Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor

PR-M11-18-NI-102
Awards

MilliporeSigma Wins Two R&D 100 Awards for Innovation in 2018

PR-M11-18-NI-101
Financing

Antios Therapeutics Raises $25 Million in Oversubscribed Series A Financing to Pursue Hepatitis B Cure

PR-M11-18-NI-100
Acquisition

Interventional Medicine Maker BTG Will Be Purchased by Boston Scientific

PAO-M11-18-NI-030
CRISPR

CRISPR Used to Edit Genes in Human Embryos

PAO-M11-18-NI-024
Launch

Perrigo Launches Its AB Rated Generic Version of Solaraze® Gel 3%

PR-M11-18-NI-100
Research

Newfound Mechanism May Yield Ways to Counter Mistaken Immune Attack on Body

PR-M11-18-NI-097
Market Prediction

Cannabis Market Worth $39.4 Billion by 2023 - Exclusive Report by MarketsandMarkets™

PR-M11-18-NI-099
FDA Inspection

Mylan Statement in Response to FDA Warning Letter Relating to Morgantown Plant

PR-M11-18-NI-093
Crohn's Disease

Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease

PR-M11-18-NI-092
New Facility

Fresenius Leases Space at Enterprise Business Park

PR-M11-18-NI-091
Launch

Astellas Global Health Foundation Launches

PR-M11-18-NI-087
Collaboration

TARGET PharmaSolutions® to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead Sciences

PR-M11-18-NI-089
Recall

Mylan Initiates Voluntary Nationwide Recall Due to the Detection of Trace Amounts of NDEA

PR-M11-18-NI-087
CRISPR

CRISPR Technology Market Worth $1,715 Million by 2023 - Exclusive Report by MarketsandMarkets™

PR-M11-18-NI-083
Oncology

World Institute of Kimchi: Function-enhanced kimchi inhibits growth of cancer cells

PR-M11-18-NI-081
Positive Opinion

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab)

PR-M11-18-NI-74
Clinical Trial

Auritec Pharmaceuticals Completes Enrollment for its Sustained-release Depot Tacrolimus Clinical Trial

PR-M11-18-NI-078
Facility

CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China

PR-M11-18-NI-085
Clinical Trial

Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism

PR-M11-18-NI-084
Oncology

New Study Makes Important Step Toward Treatment of Deadly Brain Cancer

PR-M11-18-NI-073
Finance

Kodiak Sciences Announces Third Quarter 2018 Financial Results and Recent Business Highlights

PR-M11-18-NI-071
Pricing

More Price Hikes Coming from Pfizer Next Year

PAO-M11-18-NI-018
Recall

Sandoz Issues Voluntary Recall of Losartan

PAO-M11-18-NI-016
Clinical Results

Theranica Announces Results from Pivotal Study of Device for Treating Acute Migraine

PR-M11-18-NI-066
Clinical Results

BAROnova's TransPyloric Shuttle® (TPS®) Positive Pivotal Trial Data Presented at the 2018 Obesity Week Conference

PR-M11-18-NI-070
Clinical Data

DNAtrix To Present Interim Phase 2 Results of DNX-2401 with Pembrolizumab for Glioblastoma

PR-M11-18-NI-067
Clinical Study

Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at 2018 Annual Scientific Meeting

PR-M11-18-NI-063
Oncology

Cervical Cancer Treatment: Cure Is Possible If Patients Receive Brachytherapy

PR-M11-18-NI-065
Acquisition

Synteract Acquires Pediatric CRO KinderPharm to Further Strengthen its Pediatric Center of Development

PR-M11-18-NI-064
Research

New Finding Adds Proof Microbes are at Alzheimer's "Crime Scene," Says Dr. Leslie Norins, CEO of Alzheimer's Germ Quest, Inc.

PR-M11-18-NI-062
Drug Development

Published Study: Pycnogenol® Measurably Improved Symptoms Related to Enlarged Prostate Within 60 Days

PR-M11-18-NI-061
License Agreement

Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag

PR-M11-18-NI-059
Oncology

Patients Launch New Study to Shed Light on EGFR-Positive Lung Cancers

PR-M11-18-NI-060
Innovation

NIH $1.4M Grant Supports Study into Precision Bioelectronic Medicine

PR-M11-18-NI-057
Drug Pricing

Gemini Health and Surescripts Partner to Lower Drug Costs through Prescription Price Transparency at the Point of Prescribing

PR-M11-18-NI-055
Antibiotics

Infectious Diseases Experts Convene to Explore Lifesaving Antibiotic Research Methods

PR-M11-18-NI-052
Oncology

Regen BioPharma, Inc. Reports Additional New NR2F6 Small Molecule Inhibitors

PR-M11-18-NI-048
Launch

For Eyes Launches Foundation To Provide Greater Access To Eye Care

PR-M11-18-NI-047
Research

Researchers Eye Mental Health Impacts of Hurricane Harvey

PR-M11-18-NI-046
Market Prediction

Global Crohn's Disease Therapeutics Market to 2025 with Johnson & Johnson Services Inc. Pfizer Inc. Allergan and AbbVie Dominating

PR-M11-18-NI-049
Investment

US Tax Savings Help AbbVie

PAO-M11-18-NI-012
Investment

NextCure Bags $40 Million from Eli Lilly

PAO-M11-18-NI-010
Collaboration

Sanofi and Denali Therapeutics Enter New Collaboration

PAO-M11-18-NI-008